KNApSAcK Metabolite C00048954
Metabolite
KNApSAcK Entry
| id | C00048954 |
|---|---|
| Name | Acetone |
| CAS RN | 67-64-1 |
| Standard InChI | InChI=1S/C3H6O/c1-3(2)4/h1-2H3 |
| Standard InChI (Main Layer) | InChI=1S/C3H6O/c1-3(2)4/h1-2H3 |
Cluster
| Phytochemical cluster | |
|---|---|
| KCF-S cluster | No. 5308 |
Link
ChEMBL
| By standard InChI | CHEMBL14253 |
|---|---|
| By standard InChI Main Layer | CHEMBL14253 |
KEGG
| By LinkDB | C00207 |
|---|
CTD
| By CAS RN | D000096 |
|---|
Species
Summary
List (1)
* NCBI
| KNApSAcK organism | *ID | *family | *plant class | *kingdom |
|---|---|---|---|---|
| Olea europaea | 4146 | Oleaceae | asterids | Viridiplantae |
Human Protein / Gene in interaction
1 ChEMBL Protein in interactions
| accession | description | class description | compound | assay ID (# of activities) |
# of diseases
(OMIM / KEGG) |
|---|---|---|---|---|---|
| P02545 | Prelamin-A/C | Unclassified protein | CHEMBL14253 |
CHEMBL1614544
(1)
|
11 / 10 |
CTD interaction (10)
| compound | gene | gene name | gene description | interaction | interaction type | form |
reference
pmid |
|---|---|---|---|---|---|---|---|
| D000096 | 847 |
CAT
|
catalase (EC:1.11.1.6) | Acetone results in decreased activity of CAT protein |
decreases activity
|
protein |
16169704
|
| D000096 | 595 |
CCND1
BCL1 D11S287E PRAD1 U21B31 |
cyclin D1 | Acetone results in increased expression of CCND1 mRNA |
increases expression
|
mRNA |
12720008
|
| D000096 | 1559 |
CYP2C9
CPC9 CYP2C CYP2C10 CYPIIC9 P450IIC9 |
cytochrome P450, family 2, subfamily C, polypeptide 9 (EC:1.14.13.48 1.14.13.49 1.14.13.80) | Acetone promotes the reaction [CYP2C9 protein results in increased hydroxylation of Tolbutamide] |
increases hydroxylation
/ increases reaction |
protein |
10611138
|
| D000096 | 1571 |
CYP2E1
CPE1 CYP2E P450-J P450C2E |
cytochrome P450, family 2, subfamily E, polypeptide 1 (EC:1.14.13.n7) | CYP2E1 protein results in increased metabolism of Acetone |
increases metabolic processing
|
protein |
15576447
|
| D000096 | 2263 |
FGFR2
BBDS BEK BFR-1 CD332 CEK3 CFD1 ECT1 JWS K-SAM KGFR TK14 TK25 |
fibroblast growth factor receptor 2 (EC:2.7.10.1) | Acetone results in increased expression of FGFR2 mRNA |
increases expression
|
mRNA |
12720008
|
| D000096 | 3596 |
IL13
IL-13 P600 |
interleukin 13 | [Acetone co-treated with olive oil] results in increased expression of IL13 mRNA |
affects cotreatment
/ increases expression |
mRNA |
21252390
|
| D000096 | 3565 |
IL4
BCGF-1 BCGF1 BSF-1 BSF1 IL-4 |
interleukin 4 | [Acetone co-treated with olive oil] results in increased expression of IL4 mRNA |
affects cotreatment
/ increases expression |
mRNA |
21252390
|
| D000096 | 3567 |
IL5
EDF IL-5 TRF |
interleukin 5 (colony-stimulating factor, eosinophil) | [Acetone co-treated with olive oil] results in increased expression of IL5 mRNA |
affects cotreatment
/ increases expression |
mRNA |
21252390
|
| D000096 | 3678 |
ITGA5
CD49e FNRA VLA5A |
integrin, alpha 5 (fibronectin receptor, alpha polypeptide) | Acetone results in increased expression of ITGA5 mRNA |
increases expression
|
mRNA |
12720008
|
| D000096 | 7124 |
TNF
DIF TNF-alpha TNFA TNFSF2 |
tumor necrosis factor | [Acetone co-treated with olive oil] results in increased expression of TNF mRNA |
affects cotreatment
/ increases expression |
mRNA |
21252390
|
Related Disease
Diseases related to proteins in ChEMBL interactions
OMIM (11)
| OMIM | preferred title | UniProt |
|---|---|---|
| #115200 | Cardiomyopathy, dilated, 1a; cmd1a |
P02545
|
| #212112 | Cardiomyopathy, dilated, with hypergonadotropic hypogonadism |
P02545
|
| #605588 | Charcot-marie-tooth disease, axonal, type 2b1; cmt2b1 |
P02545
|
| #181350 | Emery-dreifuss muscular dystrophy 2, autosomal dominant; edmd2 |
P02545
|
| #610140 | Heart-hand syndrome, slovenian type |
P02545
|
| #176670 | Hutchinson-gilford progeria syndrome; hgps |
P02545
|
| #151660 | Lipodystrophy, familial partial, type 2; fpld2 |
P02545
|
| #248370 | Mandibuloacral dysplasia with type a lipodystrophy; mada |
P02545
|
| #613205 | Muscular dystrophy, congenital, lmna-related |
P02545
|
| #159001 | Muscular dystrophy, limb-girdle, type 1b; lgmd1b |
P02545
|
| #275210 | Restrictive dermopathy, lethal |
P02545
|
KEGG DISEASE (10)
| KEGG | disease name | UniProt |
|---|---|---|
| H00264 | Charcot-Marie-Tooth disease (CMT) |
P02545
(related)
|
| H00294 | Dilated cardiomyopathy (DCM) |
P02545
(related)
|
| H00420 | Familial partial lipodystrophy (FPL) |
P02545
(related)
|
| H00563 | Emery-Dreifuss muscular dystrophy |
P02545
(related)
|
| H00590 | Congenital muscular dystrophies (CMD/MDC) |
P02545
(related)
|
| H00593 | Limb-girdle muscular dystrophy (LGMD) |
P02545
(related)
|
| H00601 | Hutchinson-Gilford progeria syndrome |
P02545
(related)
|
| H00663 | Restrictive dermopathy |
P02545
(related)
|
| H00665 | Mandibuloacral dysplasia |
P02545
(related)
|
| H01216 | Left ventricular noncompaction (LVNC) |
P02545
(related)
|
Diseases related to CTD interactions
8 disease from interactions of metabolites
| MeSH disease | OMIM | compound | disease name | evidence type |
reference
pmid |
|---|---|---|---|---|---|
| D003389 | D000096 | Cranial Nerve Diseases |
marker/mechanism
|
12635524
|
|
| D003556 | D000096 | Cystitis |
marker/mechanism
|
19618450
|
|
| D056486 | D000096 | Drug-Induced Liver Injury |
marker/mechanism
therapeutic |
1802361
6138230 |
|
| D007662 | D000096 | Ketosis |
marker/mechanism
|
6138230
|
|
| D009374 | D000096 | Neoplasms, Experimental |
marker/mechanism
|
9496914
|
|
| D012640 | D000096 | Seizures |
therapeutic
|
19694724
|
|
| D012878 | D000096 | Skin Neoplasms |
marker/mechanism
|
9496914
|
|
| D014555 | D000096 | Urination Disorders |
marker/mechanism
|
19618450
|